[go: up one dir, main page]

NO20050073L - Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene - Google Patents

Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene

Info

Publication number
NO20050073L
NO20050073L NO20050073A NO20050073A NO20050073L NO 20050073 L NO20050073 L NO 20050073L NO 20050073 A NO20050073 A NO 20050073A NO 20050073 A NO20050073 A NO 20050073A NO 20050073 L NO20050073 L NO 20050073L
Authority
NO
Norway
Prior art keywords
compounds
preparation
substituted
ring
diphenyllazetidinones
Prior art date
Application number
NO20050073A
Other languages
English (en)
Inventor
Heiner Glombik
Hubert Heuer
Werner Kramer
Wendelin Frick
Hans-Ludwig Schaefer
Andreas Lindenschmidt
Gerhard Jaehne
Stefanie Flohr
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20050073L publication Critical patent/NO20050073L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives ringsubstituerte difenylazetidinoner med formel 1, en fremgangsmåte for fremstilling derav, medikamenter inneholdende forbindelsene samt forbindelsenes anvendelse for behandling av hyperlipidemi, arteriosklerose og hyperkolesterolemi.
NO20050073A 2002-06-19 2005-01-06 Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene NO20050073L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10227506A DE10227506A1 (de) 2002-06-19 2002-06-19 Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PCT/EP2003/005815 WO2004000804A1 (de) 2002-06-19 2003-06-04 Ringsubstituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung

Publications (1)

Publication Number Publication Date
NO20050073L true NO20050073L (no) 2005-01-06

Family

ID=29719281

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050073A NO20050073L (no) 2002-06-19 2005-01-06 Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene

Country Status (30)

Country Link
EP (1) EP1517892B1 (no)
JP (1) JP2005533072A (no)
CN (1) CN1662493A (no)
AR (1) AR039689A1 (no)
AT (1) ATE478842T1 (no)
AU (1) AU2003242616B2 (no)
BR (1) BR0311940A (no)
CA (1) CA2490109A1 (no)
DE (2) DE10227506A1 (no)
EC (1) ECSP045498A (no)
HN (1) HN2003000183A (no)
HR (1) HRP20041203A2 (no)
IL (1) IL165791A0 (no)
MA (1) MA27252A1 (no)
MX (1) MXPA04012236A (no)
MY (1) MY135850A (no)
NO (1) NO20050073L (no)
NZ (1) NZ537304A (no)
OA (1) OA12868A (no)
PA (1) PA8576001A1 (no)
PE (1) PE20040577A1 (no)
PL (1) PL372690A1 (no)
RS (1) RS108504A (no)
RU (1) RU2315754C2 (no)
SV (1) SV2004001549A (no)
TN (1) TNSN04255A1 (no)
TW (1) TW200404774A (no)
UY (1) UY27851A1 (no)
WO (1) WO2004000804A1 (no)
ZA (1) ZA200409381B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7447226B2 (en) * 2003-10-31 2008-11-04 International Business Machines Corporation Methods and apparatus for continuous connectivity between mobile device and network using dynamic connection spreading
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP1865947A1 (en) 2005-04-04 2007-12-19 Pontificia Universidad Catolica de Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2091915A1 (de) * 2006-11-02 2009-08-26 Sanofi-Aventis Deutschland GmbH Neues mit piperazin-1-sulfonsäure substituiertes diphenylazetidinon mit verbesserten pharmakologischen eigenschaften
DE102007002260A1 (de) 2007-01-16 2008-07-31 Sanofi-Aventis Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CZ293957B6 (cs) * 1995-10-31 2004-08-18 Scheringácorporation @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports

Also Published As

Publication number Publication date
DE10227506A1 (de) 2004-01-08
PA8576001A1 (es) 2004-02-07
TW200404774A (en) 2004-04-01
ECSP045498A (es) 2005-03-10
WO2004000804A1 (de) 2003-12-31
RS108504A (sr) 2007-02-05
ZA200409381B (en) 2006-05-31
RU2315754C2 (ru) 2008-01-27
HRP20041203A2 (en) 2005-06-30
EP1517892B1 (de) 2010-08-25
OA12868A (en) 2006-09-15
EP1517892A1 (de) 2005-03-30
AU2003242616A1 (en) 2004-01-06
CN1662493A (zh) 2005-08-31
AU2003242616B2 (en) 2008-12-11
NZ537304A (en) 2005-10-28
DE50313017D1 (de) 2010-10-07
MA27252A1 (fr) 2005-03-01
MXPA04012236A (es) 2005-02-25
TNSN04255A1 (en) 2007-03-12
AR039689A1 (es) 2005-03-09
UY27851A1 (es) 2003-12-31
IL165791A0 (en) 2006-01-15
ATE478842T1 (de) 2010-09-15
PE20040577A1 (es) 2004-10-11
MY135850A (en) 2008-07-31
RU2005101091A (ru) 2005-07-10
SV2004001549A (es) 2004-03-19
JP2005533072A (ja) 2005-11-04
PL372690A1 (en) 2005-07-25
CA2490109A1 (en) 2003-12-31
HN2003000183A (es) 2003-08-01
BR0311940A (pt) 2005-04-05

Similar Documents

Publication Publication Date Title
NO20050073L (no) Ringsubstituerte difenylazetidinoner, deres fremstilling, deres anvendelse samt legemidler inneholdende forbindelsene
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
GB9914486D0 (en) Medicaments
SE9904738D0 (sv) Novel compounds
SE9904505D0 (sv) Novel compounds
GB0111523D0 (en) Chemical compounds
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
NO20062335L (no) Nye diazaspiroalkaner og deres anvendelse i behandlingen av CCR8 medierte sykdommer
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20052883L (no) Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom.
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
GB0225475D0 (en) Therapeutic agents
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
SE9903544D0 (sv) Novel compounds
AP9701041A0 (en) Pyridylpyrrole compounds.
NO20070570L (no) Forbindelser.
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
NO20020282D0 (no) Nytt difenylpiperidinderivat
MY136632A (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
NO20052182L (no) Nye forbindelser
NO20083790L (no) Nye terapeutiske kombinasjoner for behandling eller forebygging av psykotiske lidelser
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
IL176171A0 (en) N-aryl piperidine substituted biphenylcarboxamides
NO20044531L (no) Imidazolinylmetyl-aralkylsulfonamider, blandinger omfattende slike, fremgangsmate for fremstilling av slike, slike forbindelser som medikament samt anvendelse av slike forbindelser for fremstilling av medikamenter for behandling av sykdom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application